- Home
- JXG vs ALBT Comparison
JXG vs ALBT Comparison
Compare JXG & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- ALBT
- Stock Information
- Founded
- JXG N/A
- ALBT 2014
- Country
- JXG China
- ALBT United States
- Employees
- JXG N/A
- ALBT N/A
- Industry
- JXG
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JXG
- ALBT Health Care
- Exchange
- JXG Nasdaq
- ALBT Nasdaq
- Market Cap
- JXG 4.6M
- ALBT 5.7M
- IPO Year
- JXG N/A
- ALBT N/A
- Fundamental
- Price
- JXG $1.03
- ALBT $2.41
- Analyst Decision
- JXG
- ALBT
- Analyst Count
- JXG 0
- ALBT 0
- Target Price
- JXG N/A
- ALBT N/A
- AVG Volume (30 Days)
- JXG 525.9K
- ALBT 2.0M
- Earning Date
- JXG 05-15-2025
- ALBT 08-18-2025
- Dividend Yield
- JXG N/A
- ALBT N/A
- EPS Growth
- JXG N/A
- ALBT N/A
- EPS
- JXG 0.86
- ALBT N/A
- Revenue
- JXG $49,840,288.00
- ALBT $807,235.00
- Revenue This Year
- JXG N/A
- ALBT N/A
- Revenue Next Year
- JXG N/A
- ALBT N/A
- P/E Ratio
- JXG $1.19
- ALBT N/A
- Revenue Growth
- JXG 56.53
- ALBT N/A
- 52 Week Low
- JXG $0.55
- ALBT $1.87
- 52 Week High
- JXG $8.40
- ALBT $12.60
- Technical
- Relative Strength Index (RSI)
- JXG N/A
- ALBT 47.99
- Support Level
- JXG N/A
- ALBT $1.87
- Resistance Level
- JXG N/A
- ALBT $4.74
- Average True Range (ATR)
- JXG 0.00
- ALBT 0.36
- MACD
- JXG 0.00
- ALBT 0.02
- Stochastic Oscillator
- JXG 0.00
- ALBT 18.82
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.